Tests AHB-121 injection in healthy adults and people with chronic hepatitis B
Tests AHB-121 injection for safety in healthy adults and chronic hepatitis B patients.
Plain-language title generated from the registry record
Registry title: A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07884864, who can take part
Where in China
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ausper Biopharma Co., Ltd.
- Trial code
- NCT07884864
- Record updated
- 21 October 2026
- Original description
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.Read full original descriptionShow less
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AHB-121 Injection in Healthy and Chronic Hepatitis B Participants
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.
Inclusion: Sign the informed consent form and be able to complete the research as required; Age and weight meet the requirements; During the screening, the results of physical examination, vital signs, laboratory tests, electrocardiogram, etc. are normal or have no clinical significance(healthy individuals); Take effective contraceptive measures as required; During the screening, HBsAg, HBV DNA, ALT, and HBeAg meet certain indicators (CHB participants).
Exclusion: Participate in other clinical trials or receive investigational drug treatment within the specified time before screening, and have received related drug; Have received solid organ transplantation or hematopoietic stem cell transplantation before screening; Have positive urine drug screening or alcohol breath test during screening; have donated blood or lost a large amount of blood before screening, received blood transfusion, or have a blood donation plan during the study; Have a serious systemic disease or a history of malignant tumor; Have other liver diseases besides chronic HBV infection, or have liver dysfunction, significant liver fibrosis/ cirrhosis, history of liver cell carcinoma or suspected cases; Have autoimmune diseases or diseases with a risk of immune activation; Have a questionable allergy to the test drugs and their components, or have an allergic constitution; Have acute infection, major trauma or major surgery with clinical significance that has not fully recovered within the specified time before screening, or have a surgical plan during the study; Have positive screening for related infectious diseases; Have a history of drug abuse or alcoholism; or have a large amount of smoking before screening and cannot stop during the study; Have a history of fainting or hemisomnia, difficulty in blood collection, or inability to tolerate venipuncture blood collection; Have abnormal laboratory tests, vital signs or electrocardiogram results during screening and have clinical significance as judged by the researcher; Have consumed caffeine, xanthine-containing foods or beverages, or engaged in intense exercise within the specified time before administration, or have been unable to stop during the study; Have a positive pregnancy test during screening; Abnormal skin at the injection site; The researcher considers that there are other factors that make one unsuitable to participate in this trial.